Does cosentyx have any heart related tests required before prescription?

Understanding Cosentyx and Cardiovascular Risks

Cosentyx (secukinumab) is a medication used to treat various forms of psoriasis, arthritis, and other inflammatory conditions. Like all medications, it carries certain risks, including potential cardiovascular side effects. Before prescribing Cosentyx, healthcare providers require patients to undergo specific tests to assess their cardiovascular health.

Risk of Cardiovascular Events

According to the FDA, secukinumab may increase the risk of cardiovascular events such as heart attack and stroke, particularly in patients with existing cardiovascular disease or risk factors [1]. To mitigate this risk, patients must undergo tests to evaluate their cardiovascular health.

Required Tests and Exams

Before being prescribed Cosentyx, patients are typically required to undergo the following tests:

1. Full medical history: Patients must disclose their medical history, including any pre-existing cardiovascular conditions, hypertension, or other conditions that may pose a risk for cardiovascular events [2].
2. Echocardiogram: This non-invasive test uses sound waves to create images of the heart, allowing healthcare providers to assess its function and structure [3].
3. EKG (electrocardiogram): An EKG measures the electrical activity of the heart, helping to identify any irregularities or signs of underlying cardiovascular disease [4].
4. Blood pressure and lipid profile tests: These tests evaluate the patient's blood pressure and lipid levels, which are crucial for assessing cardiovascular risk [5].

Patient Selection and Monitoring

Healthcare providers carefully select patients for treatment with Cosentyx, taking into account their individual risk factors and medical history. Patients with a history of cardiovascular disease or other cardiovascular risk factors may be monitored more closely during treatment with Cosentyx [6].

Cosentyx Label and Regulatory Information

For more information on the cardiovascular risks associated with Cosentyx and the required tests and exams, please consult the medication's label and the manufacturer's website.

Sources:

[1] Food and Drug Administration. (2022). Secukinumab (Cosentyx) [Label].

[2] Amgen, Inc. (2022). Cosentyx (secukinumab) Injection [Label].

[3] Mayo Clinic. (2022). Echocardiogram.

[4] MedlinePlus. (2022). Electrocardiogram (ECG or EKG).

[5] Centers for Disease Control and Prevention. (2022). High Blood Pressure.

[6] DrugPatentWatch.com. (2022). Cosentyx (secukinumab) - Patent & Exclusivity Details.